| http://www.w3.org/ns/prov#value | - Pharma companies have a stake in corporate tax reform efforts related to foreign-source income, as well as tax incentives for R&D. Federal budget cuts threaten Medicare and Medicaid payments for drugs and adequate funding for FDA, the National Institutes of Health, and other programs involved in biomedical research and pharmaceutical utilization.
|
